TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Neuromuscular Electrical Stimulation During Immobilization Due to Ankle Fractures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Unilateral closed ankle fracture (Weber type A, B or C)~* Aged from 18-65 years~* 18.5 \< BMI \< 30 kg/m2~* Undergoing surgical treatment~Exclusion Criteria:~* Additional fractures beside ankle fracture (e.g. multi-trauma following a car accident)~* Use of oral anticoagulants such as vitamin K-antagonists (e.g. acenocoumarol and fenprocoumon) and direct-acting or new oral anticoagulants (e.g. apixaban, dabigatran and rivaroxaban).~* Any family history of thrombosis~* All co-morbidities interacting with mobility and muscle metabolism of the lower limbs (e.g. arthritis, spasticity/rigidity, all neurological disorders and paralysis).~* Myocardial infarction within the last 3 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- NMES group (Type: EXPERIMENTAL): Patients will receive twice daily sessions of neuromuscular electrical stimulation (NMES).
- Control group (Type: NO_INTERVENTION): Patients will receive daily visits by the investigator to check progress.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Participants previously enrolled in AMARANTH (NCT02245737) who meet eligibility criteria for delayed-start I8D-MC-AZFD.~Exclusion Criteria:~* Participants who participate in AMARANTH (NCT02245737) who develop new conditions precluding them from enrolling into I8D-MC-AZFD.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AZES Lanabecestat 20 milligrams (mg)/AZFD Lanabecestat 20 mg (Type: EXPERIMENTAL): Participants who received Lanabecestat 20 mg in the feeder study (AZES) were randomized to receive Lanabecestat 20 mg.
- AZES Lanabecestat 50 mg/AZFD Lanabecestat 50 mg (Type: EXPERIMENTAL): Participants who received Lanabecestat 50 mg in the feeder study (AZES) were randomized to receive Lanabecestat 50 mg.
- AZES Placebo/AZFD Lanabecestat 20 mg (Type: EXPERIMENTAL): Participants who received placebo in the feeder study (AZES) were randomized to receive Lanabecestat 20 mg.
- AZES Placebo/AZFD Lanabecestat 50 mg (Type: EXPERIMENTAL): Participants who received placebo in the feeder study (AZES) were randomized to receive Lanabecestat 50 mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity of a Single Dose of GSK Biologicals' Boostrix™ in Infants Prior to Primary Pertussis Vaccination, When Administered to Pregnant Women as Per Routine Practice in Bogota, Colombia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Criteria applicable at screening (before the birth of the infant):~* Male or female infants whose mothers have received Boostrix during their current pregnancy, as per routine practice.~* Infant whose parents, in the opinion of the investigator, can and will comply with the requirements of the protocol.~* Written informed consent obtained from both parents of the infant.~Criteria applicable at enrolment (after the birth of the infant):~* Confirmation of written informed consent obtained from both parents of the infant at the time of screening.~* Infant whose parents, in the opinion of the investigator, can and will comply with the requirements of the protocol.~Exclusion Criteria:~Criteria applicable at screening (before the birth of the infant):~* Infants whose parents are below the legal consenting age of the country.~* Infant's whose mother has multiple pregnancies.~* Infant's whose mother has any confirmed or suspected immunosuppressive or immunodeficient condition (including positive infection with human immunodeficiency virus \[HIV\]), based on medical history, physical examination or positive test result.~* Infant's whose mother is concurrently participating in another clinical study, at any time during the study period, in which the infant's mother has been or will be exposed to an investigational or a non-investigational vaccine/product.~Criteria applicable at enrolment (after the birth of the infant):~* Child in care.~* In case of multiple births.~* Infants with any confirmed or suspected immunosuppressive or immunodeficient condition , based on medical history, physical examination or positive test result.~* Infants who are concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 8 Weeks
- Healthy Volunteers: t

Study Arms:
- Second and third trimester Group (Type: OTHER): This study group will include infants whose mothers have received Boostrix during the second (21-27 weeks) and third trimester (above 28 weeks) of their pregnancy, as per routine practice.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Admitted to participating hospital with symptoms suggestive of COVID-19 infection OR develop symptoms of COVID-19 during hospitalization~2. Subject (or legally authorized representative) can provide written informed consent (in English or Spanish) affirming intention to comply with planned study procedures prior to enrollment~3. Male or female adult aged 12 years or older at the time of enrollment~4. Has laboratory-confirmed SARS-CoV-2 infection determined by a validated nucleic acid amplification assay (public health or commercial) in any respiratory specimen collected within 14 days of randomization~5. Illness of any duration that includes~   * Radiographic evidence of pulmonary infiltrates (chest X-ray or CT scan) OR~  * Clinical documentation of lower respiratory symptoms (cough, shortness of breath, wheezing) OR~  * Any documented SpO2 ≤ 94% on room air OR~  * Any inpatient initiation or supplemental oxygen regardless of documented cause~Exclusion Criteria:~1. Participating in any other clinical trial of an experimental agent for COVID-19~2. On hydroxychloroquine at any time during hospitalization, or within 180 days of hospitalization for COVID-19 regardless of indication~3. History of G6PD deficiency, cirrhosis, long QT syndrome or porphyria of any classification~4. Most recent ECG prior to time of screening with QTc of ≥500 msec~5. Known hypersensitivity to hydroxychloroquine or 4-aminoquinoline derivatives~6. Death anticipated within 48 hours of enrollment~7. Inability to obtain informed consent from the patient or designated medical decision maker

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of care (Type: ACTIVE_COMPARATOR): None
- Standard of care plus hydroxychloroquine (Type: EXPERIMENTAL): Standard of care plus hydroxychloroquine for 5 days
- Standard of care plus azithromycin (Type: EXPERIMENTAL): Standard of care plus azithromycin for 5 days
- Standard of care plus hydroxychloroquine plus azithromycin (Type: EXPERIMENTAL): Standard of care plus hydroxychloroquine plus azithromycin for 5 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Safety Mechanisms of Renal Radioablation(RSRA)for Uncontrolled Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (\>18 years)~* resistant HTN defined as daytime BP readings above 140/90 mmHg (as assessed from 24-hr ABPM))~* on 4 or more BP lowering drugs~Exclusion Criteria:~* pregnant patients~* Secondary forms of hypertension~* patients with following conditions: eGFR \<45 ml/min/1.75 m2,~* active infection,~* known coagulopathies,~* acute coronary syndrome and/or within 6 months post acute coronary event,~* clinically significant arrhythmias,~* within 6 months post stroke/TIA, severe liver disease;~* psychiatric disorders and/or otherwise unable to sign consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Resistant Hypertension (Type: None): Resistant hypertension as described as; patients with uncontrolled hypertension on 3 or more antihypertensive medications with no secondary causes for hypertension (i.e. hyperaldosteronism, renal artery stenosis)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin D and Vitamin B12 Supplementation With Pegylated Interferon-Alfa Plus Ribavirin for Treating Chronic Hepatitis C

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Genotype 1 HCV infection confirmed a positive test for anti-HCV antibody and detectable serum HCV RNA by PCR~* Pegylated Interferon-Alfa treatment naïve~* Liver biopsy with Metavir F2 or less~* Cognitive capacity to understand and sign the informed consent~Exclusion Criteria:~* HBV or HIV co-infection~* Hemoglobin level less than 10 g/dL or total neutrophil count less than 1,500/mm3 or platlet count below 75,000/mm3~* Creatinin ≥ 1.5 mg/dL~* Severe cardiopathy~* Pregnancy or impossibility to use birth control methods by the couple, or breast-feeding~* Conditions that, according to the investigator's judgement, preclude participation in the study, including clinical, cognitive or behavioural conditions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): Pegylated Interferon-Alfa plus ribavirin for 48 weeks
- Vitamins (Type: EXPERIMENTAL): Pegylated Interferon-Alfa plus ribavirin for 48 weeks together oral vitamin D 2,000 IU qd throughout, irrespective of baseline vitamin D level. Intramuscular vitamin B12 5000 UI will be given weekly in the first 12 weeks followed by a monthly injection until the end of therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Polymyxin B Hemoperfusion on Severe Sepsis Secondary to Pneumonia or Urinary Tract Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with septic shock defined by the third international consensus definitions for sepsis and septic shock~2. Newly diagnosed pneumonia or urinary tract infection (UTI) defined as the following:~   2-1. Pneumonia is defined by a new infiltrate on chest radiograph and the presence of one or several of the following signs or symptoms: cough, sputum production, dyspnea, core body temperature ≥ 38.0°C, auscultatory findings of abnormal breath sounds and rales and leukocyte count \> 10000 or \< 4000/L.~   2-2. UTI is defined by at least one clinical symptom (core body temperature ≥38.0°C, urinary urgency, polyuria, dysuria, suprapubic pain, flank pain, costovertebral angle tenderness, nausea and vomiting) and one urinary criterion (pyuria \>20 leukocytes/μL).~3. Hyperlactatemia (\>2 mmol/L)~4. Endotoxin activity assay (EAA) ≥ 0.5 units.~Exclusion Criteria:~1. Shock persisted \>12 hours before screening~2. Mechanical ventilation \>21 days~3. Uncontrolled hemorrhage~4. Thrombocytopenia (platelet count \< 30,000 cells/mm3)~5. Leukopenia (leukocyte count \< 1500 cells/mm3)~6. Suspected allergy to polymyxin~7. Females with pregnancy~8. Terminal cancer or organ failure with life expectancy less than 30 days

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention arm (Type: EXPERIMENTAL): Usual care with two sessions of 2-hour hemoperfusion with Toraymyxin in 24 hours apart

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Non-inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer (PAMOJECT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histological proven prostate cancer, locally advanced or metastatic and scheduled to receive hormonal deprivation therapy~* Life expectancy of more than 9 months~* Documented testosterone levels of ≥ 125 ng/dl measured by any laboratory or on site within the previous 6 months~Exclusion Criteria:~* Has a history of hypersensitivity to the Investigational Medicinal Product or drugs with a similar chemical structure~* Has previously received a GnRH analogue, estrogens or a steroidal anti -androgen within the last year preceding the study~* Concomitant anti-coagulation treatment~* Patient who underwent an orchidectomy or who is scheduled to receive an orchidectomy during the course of this study~* Patient with known spinal medullar compression

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): triptorelin 11.25mg given 12 weekly by subcutaneous formulation
- 2 (Type: ACTIVE_COMPARATOR): triptorelin 11.25mg given 12 weekly by intramuscular injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase I Study of Radiolabeled OTSA101-DTPA in Patients With Relapsed or Refractory Synovial Sarcoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with a documented relapsed or refractory synovial sarcoma after standard chemotherapy~2. Patients ≥18 years of age at the time of obtaining informed consent~3. Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1~4. Patients with measurable lesion~5. Patients not received any anti-malignancy agent or specified surgical intervention within 28 days or specified radiotherapy within 14 days prior to study registration.~6. Patients without any clinically significant laboratory abnormality.~7. Patients with adequate heart function as measured by echocardiography or multiple gated acquisition scan (MUGA).~8. Patients with adequate pulmonary function as measured by pulmonary function tests.~9. Patients who are either not of childbearing potential or who agree to use a contraception method during the study and for 12 months after the last dose of study drug~10. Patients must be able to understand and be willing to sign a written informed consent~Exclusion Criteria:~1. Patients with documented concurrent malignancy.~2. Patients with brain metastasis with clinical symptoms.~3. Patients with any infection requiring systemic treatment.~4. Patients with lung inflammation or pulmonary fibrosis.~5. Patients with a known history of hypersensitivities to antibody agents or serum albumin agents.~6. Patients with a known history of autoimmune diseases.~7. Patients with myocardial infarction (MI) within 6 months prior to study registration.~8. Patients with uncontrolled diseases.~9. Patients with any disease requiring continuous systemic administration of steroids or immunosuppressants.~10. Patients with evidence of active HBV, HCV or HIV infection.~11. Pregnant or breastfeeding female patients, or female patients with suspected pregnancy.~12. Patients who are participating any other investigational treatments during the study.~13. Patients with psychiatric disorders and is considered to have difficulty to study participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Study Arm, no competitor (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Aged 18-90 years~2. PaO2/FiO2 (PFI) below 200 mmHg (26.7 kPa)~3. Suspected or verified SARS-CoV-2 infection~4. At least two risk factors for increased morbidity/mortality~   * Age above 50 years~  * Hypertension~  * Cardiovascular disease~  * Diabetes or pre-diabetes~  * Active or cured cancer~  * Asthma/COPD~  * Smoking~  * D-Dimer \> 1.0 mg/L~  * Auto-immune disease~5. Documented informed consent according to ICH-GCP and national regulations~Exclusion Criteria:~1. ARDS/pneumonia caused by other viral infections (positive for other virus)~2. ARDS/pneumonia caused by other non-viral infections or trauma~3. Known pregnancy or positive pregnancy test in women of childbearing age~4. Patients with previous lung fibrosis more than 10%~5. CT- or Spirometry-verified severe COPD with Emphysema~6. Contraindication for HBO according to local guidelines~7. Not likely to need ICU admission \< 7 days of screening (Subjective criteria that may exclude any patients that fulfil the other inclusion criteria but where the treating physician suspect a spontaneous recovery)~8. Mental inability, reluctance or language difficulties that result in difficulty understanding the meaning of study participation~9. Prisoner (Exclusion criteria according to IRB at UCSD)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Hyperbaric oxygen (Type: EXPERIMENTAL): Hyperbaric oxygen 1,6-2.4 Bar for 30-60 minutes (compression/decompression time, according to local routines) in addition to best practice
- Control (Type: NO_INTERVENTION): Best practice

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Chloroquine for Mild Symptomatic and Asymptomatic COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age over 18~* A person diagnosed with COVID-19 in the past 48 hours~* Asymptomatic~Exclusion Criteria:~* chronic lung disease with chronic hypoxia~* Sleep apnea requiring BIPAP / continuous positive airway pressure~* Retinal disease~* Porphyria~* Myastenia gravis~* immunodeficiency disorders~* Hearing Disorders~* Scheduled for general anesthesia~* treatment with antibiotics or antiretroviral for any reason~* Pulse \<50~* Known Ventricular arrhythmias~* Heart Failure: Systolic or Diastolic~* kown QT prolongation~* Taking medicines that increase the risk of QT prolongation in combination with CHLOROQUINE.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- low dose chloroquine (Type: EXPERIMENTAL): oral chloroquine 125mg daily for 7 days (or until the condition worsens, whichever comes first)
- Regular dose chloroquine (Type: EXPERIMENTAL): oral chloroquine 500 mg twice daily for 7 days (or until the condition worsens, whichever comes first)
- Standard of care (Type: OTHER): The treatment is mostly supportive in character and is given, based on patient's clinical state. Antibiotics do not help patients fight novel coronavirus.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy